On Friday, GSK plc (NYSE:GSK) licensor Hansoh Pharmaceutical Group Co., Ltd. announced that ARTEMIS-008, its pivotal Phase 3 trial evaluating risvutatug rezetecan (Ris-Rez) in patients with advanced or relapsed small-cell lung cancer (SCLC), met its primary endpoint of overall survival (OS).
In the trial, conducted in patients in China, Ris-Rez demonstrated statistically significant and clinically meaningful improvements in OS compared with the standard of care, topotecan.
Consistent benefit was also observed across key secondary endpoints, including progression-free survival.
Hansoh plans to use the data for a regulatory submission in China.
Read Also: GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs First Positive Phase 3 Survival Data For A B7-H3 ADC These are the first positive Phase 3 overall survival data reported for a B7-H3-targeted antibody-drug conjugate (ADC) in any tumor type.
